Our on-going programs

MELANICa

 

Immunotherapies have revolutionized melanoma treatment by enhancing the immune response against this aggressive cutaneous cancer. However, all patients do not respond to such a therapy and some relapse within two years of treatment induction.

We have identified TNF, a small protein that is produced upon immunotherapies, as involved in the resistance of tumors to the immune system in preclinical melanoma models. Hence, anti-TNF antibodies, which block TNF, enhance the immune response against melanoma, leading to complete tumor regression.

Our project aims at evaluating the putative benefit of anti-TNF antibodies on the immune response in melanoma patients. MELANIC is coordinated by Prof. Bruno Ségui (team 4, CRCT) in collaboration with Prof. Nicolas Meyer (Onco-dermatology unit, IUCT-O and team 3, CRCT) and Prof. Maha Ayyoub (Immune monitoring core facility, IUCT-O and team 1, CRCT).

The MELANICa project is coordinated by Prof. Bruno Ségui (CRCT, team 4) in collaboration with Prof. Nicolas Meyer (IUCT-O, onco-dermatology Unit) and Prof. Maha Ayyoub (IUCT-O, immune monitoring core facility). This program received support of 100 000€ from the Claudius Regaud Institute / IUCT-O.

 

MMIL

 

Disease characterized by the multiplication of cancerous cells in the bone marrow, multiple myeloma affects each year in France about 4 000 new patients for whom the current treatments do not allow, in the majority of the cases, to obtain a complete cure.

The MMIL project aims to better understand the mechanisms of recognition and eradication of cancer cells by the immune system.

This research project is based both on the study of animal models carrying myeloma and on the analysis of patient samples that could increase the recognition of tumor cells by killer lymphocytes and improve the effectiveness of current therapies with innovative strategies.

The MMIL project is coordinated by Dr. Ludovic Martinet (CRCT, team 13) and Prof. Hervé Avet-Loiseau (IUCT-O, Genomic Unit of Myeloma). This program received support of 100 000€ from the Claudius Regaud Institute / IUCT-O.

 

CIEL

 

The CIEL project (Immune escape and innate immunity in lymphoma) is based on previous studies on immuno-escape mechanisms in lymphoma, and in particular on the development of a bioinformatics tool (called IEGS for « Immune Escape Gene Set ») to analyse tumour immune-escape status.

Pointing out a deregulation of the immune checkpoint expression in these diseases, this computer tool provides clinicians with a biomarker (here an IEGS score) that could be used on  lymphoma large cohorts to explore the links between immune-escape and the characteristics of the disease/response to treatment.

The main objectives of the CIEL project are:

  • to assess ICP expression and IEGS profile of innate immunity cells in lymphoma samples from IUCT patient cohorts, comparatively to those we reported previously for the adaptive immunity T cells,
  • to study (in particular through three-dimensional experimental models) the functional impact of this deregulation on the cytotoxic anti-tumor response,
  • and to identify one or more biomarkers predictive of immunotherapy response in lymphomas.

The CIEL project is coordinated by Dr. Camille Laurent (IUCT-O, Pathology Department) and Dr. Jean-Jacques Fournié (CRCT, team 9). This program received support of 100 000€ from the Claudius Regaud Institute / IUCT-O.